Business Context and Reporting Period
This Form 8-K Current Report for Bristol-Myers Squibb Company covers events occurring on November 20, 2006, and November 22, 2006. The filing details the creation of new direct financial obligations through the issuance of senior unsecured notes in both private and public markets.
Key Financial Metrics and Debt Issuance
The Company executed a significant debt financing program totaling €1,000,000,000 in Euro-denominated notes and $1,250,000,000 in U.S. dollar-denominated notes.
- 2016 Notes: €500,000,000 aggregate principal at 4.375% interest, maturing November 15, 2016.
- 2021 Notes: €500,000,000 aggregate principal at 4.625% interest, maturing November 15, 2021.
- 2036 Notes: $1,250,000,000 aggregate principal at 5.875% interest, maturing November 15, 2036.
Interest payments for the Euro notes are due annually on November 15, commencing November 15, 2007. The filing does not provide specific revenue, profit, cash flow, or liquidity metrics for the reporting period.
Material Changes and Covenants
The primary material change is the increase in the Company's senior unsecured indebtedness. The new Notes rank equally with all existing and future unsecured senior indebtedness. The indentures include customary covenants limiting consolidation, mergers, asset sales, the incurrence of certain liens, and sale-leaseback transactions.
Outlook, Risks, and Unusual Items
The Euro notes were issued in reliance on exemptions from the registration requirements of the Securities Act of 1933, while the 2036 Notes were issued in a registered public offering. No specific management commentary, forward-looking guidance, or unusual items regarding operational performance are disclosed in this filing.
Investor Verification Checklist
- Verify the total aggregate principal amounts: €1 billion (2016/2021 Notes) and $1.25 billion (2036 Notes).
- Confirm the interest rates: 4.375% (2016), 4.625% (2021), and 5.875% (2036).
- Review the attached Exhibits 4t, 4u, and 4s for the full text of the Note terms and covenants.
- Check subsequent filings for the use of proceeds from these issuances, as this 8-K does not specify the allocation of funds.